Search results for: Health Policy and Regulation
Filter search results
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
…Novel Diagnostics to Manage Antimicrobial Resistance. Appl Health Econ Health Policy 18, 69–79 (2020). https://doi.org/10.1007/s40258-019-00516-0 Neri, M., Hampson, G., Henshall, C. and Towse, A., 2019. HTA and payment mechanisms for…
Updated: OHE Guide to UK Health and Health Care Statistics
30 October 2013
…population estimates and projections; mortality statistics and summary measures, including life expectancy and standardisation techniques; and the collection and use of morbidity and lifestyle statistics. Section 2: Health care expenditure…
Does Government Funding Increase Public Sector Development of New Medicines?
5 March 2021
…and Figures 2017. (downloaded from https://www.ifpma.org/wp-content/uploads/2017/02/IFPMA-Facts-And-Figures-2017.pdf) Barrenho, E. and Miraldo, M., 2018. R&D Success in Pharmaceutical Markets: A Duration Model Approach. In: Health Econometrics, Contributions to Economic Analysis. [online] Emerald…
Ignoring the needs of our future workforce could have disastrous consequences for the UK NHS and its patients.
12 May 2022
…governmental efforts to increase nurses, doctors and GP recruitment and the partial restitution of the nurses’ and medical bursaries are not considered enough to address the present and future staffing…
2015 OHE Annual Lecture: Regulation, Reimbursement, and Evidence on New Medical Technologies: Experiences and Future Directions in the United States
10 June 2015
…McClellan, MD, PhD, is a Senior Fellow and Director of the Initiatives on Value and Innovation in Health Care at the Brookings Institution. His work focuses on strategies and policy…
Spotlight on OHE: Assessing Value and Balancing Needs in Health Care
15 December 2011
…focus: the financing, organisation and delivery of health care; HTA methods and processes; and the economics and regulation of the pharmaceutical and life sciences industries. Those through November are summarised…
Delivering the Triple Win: A Value-Based Approach to Pricing
20 April 2023
…healthcare system stakeholders work together to: Ensure meaningful involvement of all stakeholders in value assessment and recognition Enhance collaboration and share expertise across EU Member States Develop a shared and…
Time to Tackle the Challenges around Combination Therapies for Cancer
29 March 2021
…improving clinical development to identify optimum treatment paradigms (such as treatment durations and stopping rules that optimise health benefits and minimise adverse effects and costs). This is important but challenging….
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
2 June 2023
…objectives and policy initiatives that can facilitate progress and increase uptake: The introduction of appropriate pricing and reimbursement mechanisms The standardisation of testing and care pathways The development of infrastructure…